Encapsulated Cell Biodelivery of Transposon-Mediated High-Dose NGF to the Göttingen Mini Pig Basal Forebrain

Open Tissue Engineering and Regenerative Medicine Journal

Volumn 5, Issue 1, 2012, Pages 35-42

  Fjord Larsen, Lone ^a   Kusk, Philip ^a   Torp, Malene ^a   Sørensen, Jens Christian H ^b   Ettrup, Kaare ^b   Bjarkam, Carsten R ^b   Tornøe, Jens ^a   Juliusson, Bengt ^a   Wahlberg, Lars U ^c  

^a NsGene AS   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c NsGene Inc   (United States)

Author keywords

Alzheimer's disease; Encapsulated cell biodelivery ; G ttingen minipigs; Nerve growth factor; Preclinical testing; Sleeping beauty; Transposon

Indexed keywords

NERVE GROWTH FACTOR; POLYETHYLENE TEREPHTHALATE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL ENCAPSULATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DEVICE SAFETY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG MEGADOSE; FEMALE; FOREBRAIN; MINIPIG; NONHUMAN; PHYSICAL TOLERANCE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; TOXICITY TESTING; TRANSPOSON;

SUIDAE;

EID: 84861866391     PISSN: None     EISSN: 18750435     Source Type: Journal    
DOI: 10.2174/1875043501205010035     Document Type: Article

References (29)

1. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 677-85.
2. Schindowski K, Belarbi K, Buee L. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav 2008; 7 (Suppl. 1): 43-56.
3. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 1: CD005593.
4. O'Brien JT, Burns A. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25(8): 997-1019.
5. Hansen RA, Gartlehner G, Lohr KN, Kaufer DI. Functional outcomes of drug treatment in Alzheimer's disease: A systematic review and meta-analysis. Drugs Aging 2007; 24:155-167.
6. Salehi A, Delcroix JD, Swaab DF. Alzheimer's disease and NGF signaling. J Neural Transm 2004; 111: 323-45.
7. Lindvall O, Wahlberg LU. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? Exp Neurol 2008; 209: 82-8.
8. Fjord-Larsen L, Kusk P, Tornoe J, et al. Long-term delivery of nerve growth factor by encapsulated cell biodelivery in the Gottingen minipig basal forebrain. Mol Ther 2010; 18: 2164-72.
9. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997; 91: 501-10.
10. Ivics Z, Izsvak Z. The expanding universe of transposon technologies for gene and cell engineering. Mob DNA 2010; 1: 25.
11. Fjord-Larsen L, Kusk P, Emerich DF, et al. Increased encapsulated cell biodelivery of nerve growth factor in the brain by transposonmediated gene transfer. Gene Ther 2011; doi: 10.1038/gt.2011.178.
12. Bjarkam CR, Cancian G, Glud AN, Ettrup KS, Jorgensen RL, Sorensen JC. MRI-guided stereotaxic targeting in pigs based on a stereotaxic localizer box fitted with an isocentric frame and use of SurgiPlan computer-planning software. J Neurosci Methods 2009; 183: 119-26.
13. Schwenter F, Bouche N, Pralong WF, Aebischer P. In vivo calcium deposition on polyvinyl alcohol matrix used in hollow fiber cell macroencapsulation devices. Biomaterials 2004; 25: 3861-8.
14. Kordower JH, Chen EY, Mufson EJ, Winn SR, Emerich DF. Intrastriatal implants of polymer encapsulated cells genetically modified to secrete human nerve growth factor: trophic effects upon cholinergic and noncholinergic striatal neurons. Neuroscience 1996; 72: 63-77.
15. Klein RL, Hirko AC, Meyers CA, Grimes JR, Muzyczka N, Meyer EM. NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Brain Res 2000; 875: 144-1451.
16. Jonhagen ME. Nerve growth factor treatment in dementia. Alzheimer Dis Assoc Disord 2000; 14 (Suppl. 1): S31-S38.
17. Montero CN, Hefti F. Rescue of lesioned septal cholinergic neurons by nerve growth factor: specificity and requirement for chronic treatment. J Neurosci 1988; 8: 2986-2999.
18. Niewiadomska G, Komorowski S, Baksalerska-Pazera M. Amelioration of cholinergic neurons dysfunction in aged rats depends on the continuous supply of NGF. Neurobiol Aging 2002; 23: 601-613.
19. Mai JK, Paxinos G, Voss T. Atlas of the human brain. 3rd ed. USA: Academic Press, Elsevier 2008.
20. Frim DM, Uhler TA, Short MP, et al. Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. Neuroreport 1993; 4: 367-70.
21. Hoffman D, Breakefield XO, Short MP, Aebischer P. Transplantation of a polymer-encapsulated cell line genetically engineered to release NGF. Exp Neurol 1993; 122: 100-6.
22. Conner JM, Darracq MA, Roberts J, Tuszynski MH. Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate corticalcholinergic innervation. Proc Natl Acad Sci USA 2001; 98: 1941-6.
23. Grabundzija I, Irgang M, Mates L, et al. Comparative analysis of transposable element vector systems in human cells. Mol Ther 2010; 18: 1200-9.
24. Hill DJ, Whittaker AK. Mineralization of radiation-crosslinked polyvinyl alcohol/polyvinyl pyrrolidone hydrogels. J Biomed Mater Res A 2007; 83: 354-61.
25. Zhang H, Lewis CG, Aronow MS, Gronowicz GA. The effects of patient age on human osteoblasts' response to Ti-6Al-4V implants in vitro. J Orthop Res 2004; 22: 30-8.
26. Daamen WF, Nillesen ST, Hafmans T, Veerkamp JH, van Luyn MJ, Van Kuppevelt TH. Tissue response of defined collagenelastin scaffolds in young and adult rats with special attention to calcification. Biomaterials 2005; 26: 81-92.
27. Fournier E, Passirani C, Montero-Menei CN, Benoit JP. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials 2003; 24: 3311-31.
28. Bridges AW, Garcia AJ. Anti-inflammatory polymeric coatings for implantable biomaterials and devices. J Diabetes Sci Technol 2008; 2: 984-94.
29. Zhong Y, Bellamkonda RV. Dexamethasone-coated neural probes elicit attenuated inflammatory response and neuronal loss compared to uncoated neural probes. Brain Res 2007; 1148: 15-27.